Skip to main content
. 2019 Oct 22;2019(10):CD005015. doi: 10.1002/14651858.CD005015.pub4

Tiryaki 2018.

Methods

  • Study design: parallel RCT

  • Study duration: not reported

  • Duration of follow‐up: 12 months
Participants

  • Country: Turkey

  • Setting: single centre

  • Inclusion criteria: nondiabetic kidney transplant recipients; eGFR > 30 mL/min/1.73 m2

  • Number: treatment group (40); control group (40)

  • Mean age ± SD: 43.68 ± 14.58 years

  • Sex (M/F): 44/36

  • Exclusion criteria: receiving RAS blockers and diuretics; SCr >1.5 mg/dL; albuminuria > 1 g
Interventions Treatment group

  • Calcitriol: 0.25 µg/d


Control group

  • No treatment


Co‐interventions

  • Not reported
Outcomes

  • eGFR

  • UACR
Notes

  • Funding source: not reported

ABD ‐ adynamic bone disease; ALP ‐ alkaline phosphatase; BMD ‐ bone mineral density; CRP ‐ C‐reactive protein; (e)GFR ‐ (estimated) glomerular filtration rate; (i)PTH ‐ (intact) parathyroid hormone; MI ‐ myocardial infarction; RAS ‐ renin‐angiotensin system; SCr ‐ serum creatinine; UACR ‐ urinary albumin‐creatinine ratio; UPCR ‐ urinary protein‐creatinine ratio